Clovis (NASDAQ:CLVS) was forced to admit an unpleasant defeat after data emerged showing no significant difference in survival rates for advanced pancreatic cancer patients treated with the company's drug candidate CO-101 versus the current chemotherapy treatment, gemcitabine. The news caused the stock to drop by nearly 40% on Monday. In this video, Motley Fool health care analyst Brenton Flynn tells us how the company plans to move forward in the face of these big losses, and why this has been a difficult space for other companies as well.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Clovis Gets Creamed After Cancer Drug Failure
NASDAQ: CLVS
Clovis Oncology

Another one bites the dust.
Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.